Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir.

Furfine ES, Baker CT, Hale MR, Reynolds DJ, Salisbury JA, Searle AD, Studenberg SD, Todd D, Tung RD, Spaltenstein A.

Antimicrob Agents Chemother. 2004 Mar;48(3):791-8.

2.

Metabolic disposition and pharmacokinetics of [14C]-amprenavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, administered as a single oral dose to healthy male subjects.

Sadler BM, Chittick GE, Polk RE, Slain D, Kerkering TM, Studenberg SD, Lou Y, Moore KH, Woolley JL, Stein DS.

J Clin Pharmacol. 2001 Apr;41(4):386-96.

PMID:
11304895
3.

Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor.

Polli JW, Jarrett JL, Studenberg SD, Humphreys JE, Dennis SW, Brouwer KR, Woolley JL.

Pharm Res. 1999 Aug;16(8):1206-12.

PMID:
10468021
4.
5.

A robotics-based liquid chromatographic assay for the measurement of atovaquone in plasma.

Studenberg SD, Long JD, Woolf JH, Bruner CJ, Wilson D, Woolley JL.

J Pharm Biomed Anal. 1995 Oct;13(11):1383-93.

PMID:
8634356
6.

Characterization of p-hydroxyphenobarbital glucuronide generated from immobilized rat hepatic UDP-glucuronosyltransferase.

Studenberg SD, Price-Raybuck DL, Unger SE, Shockcor J, Brouwer KL.

J Pharm Sci. 1995 Sep;84(9):1134-6. No abstract available.

PMID:
8537894
7.
11.

Supplemental Content

Loading ...
Support Center